This site is still under development. Information, features, and some organizational
aspects of the data still need further work and will change as we continue building.

Zolinza

Hover over a term you want explained. If you need more details, then click on the term and a new tab will open with a full details page.

What Zolinza Means in Everyday Medical Language

Zolinza is the brand name for the drug vorinostat, which is also called SAHA or suberoylanilide hydroxamic acid. It is a medicine used to treat a type of skin lymphoma called cutaneous T-cell lymphoma (CTCL). This drug works by blocking enzymes known as histone deacetylases (HDACs). These enzymes help cancer cells grow and divide, so by blocking them, Zolinza may slow down or stop the growth of cancer cells.

Why Zolinza Can Matter in Cancer Care

Zolinza offers an important treatment option for people whose cutaneous T-cell lymphoma has not improved or has returned after other treatments. It was the first drug of its kind approved by the U.S. Food and Drug Administration (FDA) for this use. Beyond CTCL, Zolinza is being studied in clinical trials to see if it can help treat other types of cancer, although these uses are still experimental. This means it might become useful for more patients in the future, but its use outside of approved treatments is still being researched.

What Patients Might See or Hear About Zolinza

Patients may hear the terms Zolinza, vorinostat, or SAHA during discussions about treatment options, in medical reports, or when reviewing clinical trial information. Because these names all refer to the same drug, it can be confusing. You might also see Zolinza mentioned in test results or treatment plans. It’s important to ask your healthcare team what the term means in your specific situation.

Where Zolinza Might Appear in Medical Information

Zolinza can appear in medical records, treatment plans, drug information sheets, or clinical trial listings. It may be listed under any of its names—Zolinza, vorinostat, SAHA, or suberoylanilide hydroxamic acid. Comparing these names can help avoid confusion and better understand how it relates to your care.

What Seeing the Term Does Not Automatically Mean

Seeing the term Zolinza does not mean you have a diagnosis or that this drug is definitely part of your treatment. It is simply the name of a medicine that may be used. Whether Zolinza is right or safe for you depends on many factors that only your healthcare provider can evaluate.

Common Questions to Ask Your Care Team

If Zolinza comes up in your care, you might ask: What is Zolinza and how does it work? Is Zolinza part of my treatment plan? What are the possible benefits and side effects? Are there clinical trials involving Zolinza that I might consider? How will we know if Zolinza is working? These questions can help you understand your care better.

How to Read the Term in Context

Because Zolinza has several names and is used in different ways, it’s important to look at the full context—such as your type of cancer, treatment history, and current plan—when you see this term. Don’t rely on the word alone to make decisions or assumptions. Always discuss what it means for you with your healthcare team.

Safety and Next Steps

This information about Zolinza is educational and does not replace medical advice. Only your healthcare provider can decide if Zolinza is appropriate and safe for you. If you see Zolinza mentioned in your medical records or hear about it in your care, the best next step is to ask your healthcare team what it means in your specific situation and how it fits into your treatment plan.

Sources

Public source information used for this glossary entry includes: